SCHEMBL9933243

SCHEMBL9933243

CC(C)(C)OC(=O)N1CCN(Cc2ccon2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
ALDH1A1 P00352 4/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
VEGFA P15692 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SCD5 Q86SK9 1/20 0.43
POLB P06746 2/20 0.42
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TERT O14746 1/20 0.42
HDAC4 P56524 1/20 0.42
CCNK O75909 1/20 0.41
CDK12 Q9NYV4 1/20 0.41
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207984 0.80 CHRM2 (0.44) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL25229156 0.77 SCD5 (0.53) MEN1KMT2ASCD5POLBUSP2
SCHEMBL17092833 0.77 GPR119 (0.46) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL2137893 0.77 ALDH1A1 (0.68) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL4285303 0.77 TBK1 (0.47) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL15093975 0.77 CCNK (0.48) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL31227168 0.77 POLB (0.50) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL18429008 0.76 GPR119 (0.53)
SCHEMBL15093710 0.76 SCD5 (0.57) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL24765850 0.76 VEGFA (0.48) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CHRM2 68/4885CHRM4 204/4885CHRM1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.